Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Free Cash Flow (2020 - 2023)

Candel Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$7.9 million for Q4 2023.

  • For Q4 2023, Free Cash Flow fell 9.76% year-over-year to -$7.9 million; the TTM value through Dec 2023 reached -$34.7 million, down 6.07%, while the annual FY2024 figure was -$27.0 million, 22.08% up from the prior year.
  • Free Cash Flow for Q4 2023 was -$7.9 million at Candel Therapeutics, up from -$8.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.3 million in Q3 2020 and bottomed at -$10.9 million in Q1 2023.
  • The 4-year median for Free Cash Flow is -$7.2 million (2022), against an average of -$6.9 million.
  • The largest annual shift saw Free Cash Flow crashed 417.85% in 2021 before it increased 16.07% in 2023.
  • A 4-year view of Free Cash Flow shows it stood at -$4.3 million in 2020, then crashed by 32.79% to -$5.7 million in 2021, then decreased by 24.71% to -$7.2 million in 2022, then fell by 9.76% to -$7.9 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Free Cash Flow are -$7.9 million (Q4 2023), -$8.5 million (Q3 2023), and -$7.4 million (Q2 2023).